Last updated 2026-06-18
- Acquired by Roche, Sep 2025
- Raised $60M funding round, Oct 2018
Total raised
$1.1B
Last: 2018-10
Stage
Public
Founded
2018
Headcount
142
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
The company’s lead product candidate, pegozafermin (BIO89-100), is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company believes that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as MASH and SHTG.
Funding history · 1 round · $1.1B total
2018-10
Q&A
- What is 89bio's primary focus?
- 89bio is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases.
- What is 89bio's lead product candidate?
- 89bio's lead product candidate is pegozafermin (BIO89-100), an investigational glycopegylated FGF21 analog.
- What conditions is pegozafermin being evaluated for?
- Pegozafermin is currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
- When was 89bio founded?
- 89bio was founded in January 2018.
- What is 89bio's current market capitalization?
- 89bio's market capitalization is $2,203,627,632 USD.
- What is the total amount of funding 89bio has raised?
- 89bio has raised a total of $1,146,000,000 USD.
- When was 89bio's last funding round and who were the investors?
- 89bio's last funding round occurred in October 2018, with investors including RA Capital Management and Pontifax.
- What is the current status of 89bio?
- 89bio is currently active and was acquired by Roche in September 2025.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
biopharmaceuticaldiabetespharmaceuticalsbiotechnologylife-sciencespatientsgastroenterology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | 89bio.com |
|---|---|
| linkedin.com/company/54350802 | |
| Wikipedia | he.wikipedia.org/wiki/89%D7%91%D7%99%D7%95 |
| Wikidata | wikidata.org/wiki/Q136365899 |
Identifiers & details
| Founded | 2018-1 |
|---|---|
| Employees (exact) | 142 |
| Offices | San Francisco; San Francisco |
| Market cap | $2.2B |
| Status reason | Acquired by Roche on Sep, 2025 |
| Wikidata QID | Q136365899 |
Acquisitions & public offerings
Acquired by Roche 2025-09
Radar intelligence
Patents
| EPO | 13 |
|---|
Publications (Crossref)
| Works | 8 |
|---|
Web history (Wayback)
| Domain | 89bio.com |
|---|
Wikidata
| QID | Q136365899 |
|---|